INT (Integrated Nano-Technologies) presses on with portable electronic DNA technology:
This article was originally published in Clinica
Executive Summary
Integrated Nano-Technologies (INT) predicts that its portable biological agent detection system could be ready for commercialisation in early 2004. The BioDetect system is a low cost, electronic-based, DNA detection system that can test for agents, such as anthrax, smallpox and SARS in minutes, says the Rochester, New York firm. Weighing around 12lbs, the simple-to-operate device can be used independently or integrated into existing systems, and requires minimal sample preparation. It consists of an electronic analyser and single-use, disposable test cards. It can test for hundreds of targets from a single sample. The system is expected to undergo testing shortly.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.